Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00844285 · ClinicalTrials.gov registry record
SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry
A clinical trial, sponsored by UCB Biosciences.
- Completed
- Registry status
- 3,072
- Enrollment target
NCT00844285: Completed study, sponsored by UCB Biosciences.
NCT00844285 is a clinical trial that has completed, run by UCB Biosciences. The registered enrollment target is 3,072 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00844285 has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- 3,072 participants
- Enrollment target
Study Summary
The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and it's objective is to monitor patients for approximately 8 years.
Primary Outcome
Incidence rate is defined as the number of participants experiencing the event of interest divided by the number person-years without an event (time up to the event for participants experiencing an event, and the full study time for those without). Adverse events of interest included malignant or unspecified tumor, serious infections, opportunistic infections, serious cardiovascular events, congestive heart failure, demyelinating-like disorders, aplastic anemia, pancytopenia, thrombocytopenia, n
Interventions
- DRUG Cimzia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,072 participants |
| Start Date | 2009-01-30 |
| Est. Completion | 2020-08-21 |
What the finished NCT00844285 record still lists
NCT00844285 is an observational study that tracks outcomes without assigning an intervention. Its 3,072 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Cimzia is the first listed.
NCT00844285 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00844285 about?
NCT00844285 is a clinical study titled "SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry". The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and it's objective is to monitor patients for approximately 8 years.
What is the current status of trial NCT00844285?
This trial is currently completed. The enrollment target is 3,072 participants. The study started on 2009-01-30. Estimated completion is 2020-08-21.
What interventions are being tested in trial NCT00844285?
The interventions under investigation include: Cimzia (DRUG).
Who is sponsoring clinical trial NCT00844285?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06667700 · 3,082 participants · Phase 3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- NCT05534243 · 3,090 participants · NA
The ED-AWARENESS-2 Trial
- NCT04722822 · 3,100 participants · NA
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
- NCT07116967 · 3,040 participants · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI